心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Heart：IABP可改善高危再灌注治疗患者远期生存

2013-07-30 高晓方 译 cmt

再灌注治疗IABPHEART
关注

中国和美国一项联合荟萃分析表明，在接受高危再灌注治疗的患者中，辅助主动脉内球囊反搏（IABP）应用可改善远期生存率。论文于7月25日在线发表于《心脏》（Heart）。 研究者对Pubmed、Cochrane图书馆和Clinicaltrials.gov数据库进行了检索，并纳入了在高危再灌注治疗患者中对比IABP和非IABP的随机临床事件。主要转归指标为早期（30天）和远期（≥6个月）死亡率。 结

中国和美国一项联合荟萃分析表明，在接受高危再灌注治疗的患者中，辅助主动脉内球囊反搏（IABP）应用可改善远期生存率。论文于7月25日在线发表于《心脏》（Heart）。

研究者对Pubmed、Cochrane图书馆和Clinicaltrials.gov数据库进行了检索，并纳入了在高危再灌注治疗患者中对比IABP和非IABP的随机临床事件。主要转归指标为早期（30天）和远期（≥6个月）死亡率。

结果显示，共有涉及2037例高危患者的10项随机试验符合纳入标准。IABP组和非IABP组的早期死亡率无显著差异（OR 0.79）。然而，IABP组的远期死亡率显著降低（OR 0.63），并且在接受经皮冠脉介入治疗的亚组患者中上述效应更为显著（OR 0.55）。进一步分析显示，IABP应用与30天再缺血率（OR 0.62）以及再缺血和心衰事件复合终点（OR 0.75）风险降低相关。未观察到显著异质性。

Chen S, Yin Y, Ling Z, Krucoff MW.Short and long term effect of adjunctive intra-aortic balloon pump use for patients undergoing high risk reperfusion therapy: a meta-analysis of 10 international randomised trials.Heart. 2013 Jul 25. [Epub ahead of print]

PMID:
23886602

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1355785, encodeId=96a81355e85d4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489069, encodeId=d39f148906986, content=<a href='/topic/show?id=7b2130649c9' target=_blank style='color:#2F92EE;'>#再灌注治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30649, encryptionId=7b2130649c9, topicName=再灌注治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e33a8492666, createdName=xjy05, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562182, encodeId=89ab1562182b2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615303, encodeId=f68c161530386, content=<a href='/topic/show?id=1e2c92e53e' target=_blank style='color:#2F92EE;'>#IABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9275, encryptionId=1e2c92e53e, topicName=IABP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cba419597616, createdName=ms4964546379600229, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049810, encodeId=2adf20498103c, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sun Mar 16 21:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=)]
    2013-08-01 zhaojie88

    #ART#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1355785, encodeId=96a81355e85d4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489069, encodeId=d39f148906986, content=<a href='/topic/show?id=7b2130649c9' target=_blank style='color:#2F92EE;'>#再灌注治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30649, encryptionId=7b2130649c9, topicName=再灌注治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e33a8492666, createdName=xjy05, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562182, encodeId=89ab1562182b2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615303, encodeId=f68c161530386, content=<a href='/topic/show?id=1e2c92e53e' target=_blank style='color:#2F92EE;'>#IABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9275, encryptionId=1e2c92e53e, topicName=IABP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cba419597616, createdName=ms4964546379600229, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049810, encodeId=2adf20498103c, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sun Mar 16 21:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=)]
    2013-08-01 xjy05

    #再灌注治疗#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1355785, encodeId=96a81355e85d4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489069, encodeId=d39f148906986, content=<a href='/topic/show?id=7b2130649c9' target=_blank style='color:#2F92EE;'>#再灌注治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30649, encryptionId=7b2130649c9, topicName=再灌注治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e33a8492666, createdName=xjy05, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562182, encodeId=89ab1562182b2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615303, encodeId=f68c161530386, content=<a href='/topic/show?id=1e2c92e53e' target=_blank style='color:#2F92EE;'>#IABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9275, encryptionId=1e2c92e53e, topicName=IABP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cba419597616, createdName=ms4964546379600229, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049810, encodeId=2adf20498103c, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sun Mar 16 21:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=)]
    2013-08-01 slcumt

    #HEART#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1355785, encodeId=96a81355e85d4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489069, encodeId=d39f148906986, content=<a href='/topic/show?id=7b2130649c9' target=_blank style='color:#2F92EE;'>#再灌注治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30649, encryptionId=7b2130649c9, topicName=再灌注治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e33a8492666, createdName=xjy05, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562182, encodeId=89ab1562182b2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615303, encodeId=f68c161530386, content=<a href='/topic/show?id=1e2c92e53e' target=_blank style='color:#2F92EE;'>#IABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9275, encryptionId=1e2c92e53e, topicName=IABP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cba419597616, createdName=ms4964546379600229, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049810, encodeId=2adf20498103c, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sun Mar 16 21:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=)]
    2013-08-01 ms4964546379600229

    #IABP#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1355785, encodeId=96a81355e85d4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489069, encodeId=d39f148906986, content=<a href='/topic/show?id=7b2130649c9' target=_blank style='color:#2F92EE;'>#再灌注治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30649, encryptionId=7b2130649c9, topicName=再灌注治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e33a8492666, createdName=xjy05, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562182, encodeId=89ab1562182b2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615303, encodeId=f68c161530386, content=<a href='/topic/show?id=1e2c92e53e' target=_blank style='color:#2F92EE;'>#IABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9275, encryptionId=1e2c92e53e, topicName=IABP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cba419597616, createdName=ms4964546379600229, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049810, encodeId=2adf20498103c, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sun Mar 16 21:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=)]
    2014-03-16 wleon8895

    #ABP#

    0

相关资讯

STROKE:脑梗vs.心梗：早期再灌注治疗的比较

       最近在线发表于《卒中》杂志的一项对比分析研究表明，与心肌梗死早期开展血管再灌注治疗，且完全再灌注率高相比，脑梗死的再灌注治疗起步晚，完全再灌注率低。缺血性脑卒中的再灌注治疗需要我们更进一步的努力和研究。 （与心肌梗死相比，脑梗患者部分及完全再灌注率均较低）        研究者在文